The Zhitong Finance App learned that the latest data from the Hong Kong Stock Exchange shows that on August 5, Genecare Development Limited reduced its holdings of Pharmaceutical Jieankang-B (02617) by 467,500 shares, at a price of HK$125,786 per share, for a total amount of about HK$5.885 million. After the holdings were reduced, the latest number of shares held was approximately 21.4929 million shares, and the latest shareholding ratio was 6.87%.

This transaction involves other related parties: Tan Qingfen Chen, Ghalibo (PTC) Limited, Morningside Holdings (Asia) Limited, Morningside Bio-Ventures Limited, and Morningside Venture (I) Investments Limited.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.